Publications
Specialty
Search
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
05/29/2024
“These findings suggest that orange peels, often discarded as waste in the citrus industry, can be repurposed into valuable health-promoting ingredients, such as diet supplements or food ingredients,” said researcher Yu Wang.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
05/29/2024
The trial results, which are the first to be published from this international collaborative project, contradict the prevailing theory that SGLT2 inhibitors reduce congestion through diuresis or increased urine production.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
05/29/2024
Royal Philips announced that the first hospitals in Hong Kong have started using Philips real-time 3D Intracardiac Echocardiography (ICE) catheter – VeriSight Pro – to aid minimally-invasive image-guided procedures. It is the first time the VeriSight Pro catheter, which is guided through a patient’s blood vessels until it lies directly inside the chambers of the heart, has been used clinically outside the US or Canada.
Cath Lab Digest
05/29/2024
My heart is still in the cath lab, always and forever,” says Cathie Biga, MSN, FACC, the 2024-2025 President of the American College of Cardiology (ACC). “[Even as] VP of a hospital, I used to go to the cath lab just to get my sanity back.”
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
05/29/2024
Corveus Medical has developed a catheter to help the millions of congestive heart failure patients around the world, specifically those who are unresponsive to current treatments. This one-time procedure provides a minimally invasive solution to essentially “switch off” the nerve signal, reducing the progression of the disease.
First Report Managed Care
05/29/2024
During a recent webinar hosted by the Drug Channels Institute, Adam Fein, PhD, discussed the specifics of the Inflation Reduction Act (IRA) and its potential impacts and timeline. First Report Managed Care connected with other managed care experts to provide their insights on the IRA’s drug-related provisions to help give a clear picture to stakeholders who may be impacted by the IRA.
Oncology
05/29/2024
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
Vascular Disease Management, CardioVascular, Journal of Invasive Cardiology
05/29/2024
Hong Kong selected as the pioneering international location for integrating Philips’ VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter into routine clinical practice
International roll-out underscores Philips’ commitment to driving healthcare innovation and enhancing patient outcomes worldwide
May 28, 2024 – Amsterdam, the Netherlands and Hong Kong – Royal Philips, a global leader in health technology, today announced that the fir
EMSWorld
05/29/2024
The event showcased a statewide ambulance procession, a family fun day with Stop the Bleed and CPR demos, an interactive Touch-a-Truck display, and a concert featuring Taylor Ingle, Corey Smith, and The Frontmen-Larry Steward of Restless Heart, and more.
Vascular Disease Management, CardioVascular
05/28/2024
At LINC, Dr Patrone discussed a new project based on the Sentante, a fully robotic teleoperated system for endovascular interventions that has been created by UAB Inovatyvi Medicina (Kaunas, Lithuania).
Vascular Disease Management, CardioVascular
05/28/2024
The case for mechanical thrombectomy as a means to eliminate post-thrombotic syndrome (PTS) was discussed today by Manuela Konert, a consultant interventionalist and head of the venous centre at University Hospital Leipzig, Germany.
ePlasty, Surgery
05/28/2024
Allograft skin for burn care is presented for a 35-year-old male who was admitted to the burn center after he threw gasoline onto a bonfire.
EP Lab Digest
05/28/2024
• Hong Kong selected as the pioneering international location for integrating Philips’ VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter into routine clinical practice
• International roll-out underscores Philips’ commitment to driving healthcare innovation and enhancing patient outcomes worldwide
Wound Care
05/28/2024
A first-in-human study of SoftOx Biofilm Eradicator (SBE), composed of hypochlorous acid and acetic acid with strong broad-spectrum antimicrobial activity, demonstrated the safe use of SBE and SOC and promising trends in a biofilm eradicator and its effect on wound healing. AWC
Wound Care
05/28/2024
Xtant Medical, an enterprise focused on surgical solutions for spinal disorders, announced it has entered the wound care market with the full commercial launch of two amniotic membrane allografts, SimpliGraft and SimpliMax.
Wound Care
05/28/2024
A 200 HCP survey found 75% agreed that the need to bridge makes tNPWT application more complicated. When a patient is lying/resting on the tube and would be at risk of a PI, 36% said that a soft port could eliminate the need to bridge. SAWC Spring 2024 poster
Wound Care
05/28/2024
A recent evaluation confirmed that the use of an AI-based Smart Diabetic Foot Ulcer Scoring System is a valuable diagnostic tool for healthcare professionals and can significantly improve the care standards in the field of diabetic foot ulcer assessment. Sci Rep
Wound Care
05/28/2024
A 20-patient study found a combination of limited debridement and application of ReCell for treatment of second-degree burns was effective with short healing time, mild scar formation and little damage to the donor skin area. J Plastic Surg
Wound Care
05/28/2024
Legacy Medical Consultants is initiating a 120-patient interventional study comparing SOC to Orion TM Amniotic Membrane for the treatment of DFUs. The primary outcome measure is incidence of complete wound closure at 12 weeks. The estimated study completion date is 7/25. clinicaltrials.gov
Wound Care
05/28/2024
PolarityTE announced the company has secured $22.5MM in financing to advance SkinTE Phase III Pivotal Study in DFUs. COVER DFUS II will enroll up to 120 patients at up to 20 clinical sites in the US. The primary endpoint is percent DFUs closed at 12 weeks.